Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes
Authors
Keywords
-
Journal
TUMOR BIOLOGY
Volume 41, Issue 1, Pages 101042831881541
Publisher
SAGE Publications
Online
2019-01-11
DOI
10.1177/1010428318815413
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis
- (2018) Grace H. Tang et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- NRF2 addiction in cancer cells
- (2018) Hiroshi Kitamura et al. CANCER SCIENCE
- AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complex
- (2018) Yi-Shu Wang et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Nrf2 attenuates inflammatory response in COPD/emphysema: Crosstalk with Wnt3a/β-catenin and AMPK pathways
- (2018) Wenhui Cui et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism
- (2018) Mingzhu Bai et al. ONCOGENE
- Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
- (2018) Antonio Cuadrado et al. PHARMACOLOGICAL REVIEWS
- Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway
- (2017) Chenxiao Yu et al. International Journal of Biological Sciences
- Breast cancer
- (2017) Nadia Harbeck et al. LANCET
- The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy
- (2017) Nelli Roininen et al. Oxidative Medicine and Cellular Longevity
- Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
- (2016) Angiolo Gadducci et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Current Therapies for the Medical Management of Diabetes
- (2016) Silvio E. Inzucchi et al. OBSTETRICS AND GYNECOLOGY
- Molecular targets of metformin antitumor action
- (2016) Stanisław Sośnicki et al. Pharmacological Reports
- Pre-existing diabetes and breast cancer prognosis among elderly women
- (2015) J Luo et al. BRITISH JOURNAL OF CANCER
- Metformin Action: Concentrations Matter
- (2015) Ling He et al. Cell Metabolism
- Therapeutic Concentrations of Metformin: A Systematic Review
- (2015) Farshad Kajbaf et al. CLINICAL PHARMACOKINETICS
- Keap1 expression has independent prognostic value in pancreatic adenocarcinomas
- (2015) Joel Isohookana et al. Diagnostic Pathology
- Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction
- (2015) Poliana Camila Marinello et al. TUMOR BIOLOGY
- Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer
- (2014) Xiu-Feng Hu et al. Asian Pacific Journal of Cancer Prevention
- Estrogen increases Nrf2 activity through activation of the PI3K pathway in MCF-7 breast cancer cells
- (2014) Juanjuan Wu et al. EXPERIMENTAL CELL RESEARCH
- Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia
- (2014) Ghorbangol Ashabi et al. METABOLIC BRAIN DISEASE
- Metformin Induces Apoptosis and Cell Cycle Arrest Mediated by Oxidative Stress, AMPK and FOXO3a in MCF-7 Breast Cancer Cells
- (2014) Eveline A. I. F. Queiroz et al. PLoS One
- Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway
- (2014) C. Gorrini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NRF2 immunolocalization in human breast cancer patients as a prognostic factor
- (2013) Yoshiaki Onodera et al. ENDOCRINE-RELATED CANCER
- Metformin and cancer
- (2013) Christos V. Rizos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Regulation of Nrf2—an update
- (2013) Suryakant K. Niture et al. FREE RADICAL BIOLOGY AND MEDICINE
- Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways
- (2013) Minh Truong Do et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Diabetes and breast cancer risk: a meta-analysis
- (2012) P Boyle et al. BRITISH JOURNAL OF CANCER
- AberrantKeap1methylation in breast cancer and association with clinicopathological features
- (2012) Raffaela Barbano et al. Epigenetics
- Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas
- (2011) Peeter Karihtala et al. BMC CANCER
- Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features
- (2010) L. M. Solis et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now